GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

Consequently, people using GLP-1 medications for weight loss may litigate ... For instance, at the start of 2024, the US list prices of Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly) increased ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

“The recent explosion in irresponsible and misleading advertising about compounded GLP-1 drugs ... when both drugs were added to the FDA's shortage list. When the FDA removed tirzepatide ...